1

1 Title: Association Between Birth Region and Time to Tuberculosis Diagnosis After US Entry

2 Among Non–US-Born Persons

3 Authors: Amish Talwar, Rongxia Li, Adam J. Langer

4 Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.

5 Talwar, R. Li, A.J. Langer)

6

7 Abstract – 143 words

8 Approximately 90% of US tuberculosis (TB) cases among non–US-born persons are attributable to progression of latent TB infection to TB disease. Using survival analysis, we investigated if 9 birthplace is associated with time of progression to TB disease among non–US-born persons. We 10 derived a Cox regression model comparing differences in time to TB diagnosis after US entry 11 among 19 global birth regions, adjusting for sex, birth year, and age at diagnosis. Compared with 12 persons from Western Europe, the adjusted hazard rate of developing TB was significantly 13 14 higher (p ≤ 0.05) for persons from all other regions, except North America and Northern Europe, and highest among persons from Middle Africa (adjusted hazard ratio = 7.0; 95% confidence 15 16 interval: 6.5–7.4). Time to TB diagnosis among non–US-born persons therefore varied by birth 17 region, which represents an important prognostic indicator for progression to TB disease.

2

18 **Text** – **3,452 words**

19 Introduction

20	The majority of incident tuberculosis (TB) cases in the United States occurs among non-
21	US-born persons. During 2018, 70.2% of TB disease cases occurred among non-US-born
22	persons, and 46.6% of those cases were diagnosed ≥ 10 years after arrival to the United States
23	(1). Although TB disease can result from recent person-to-person transmission, it is more
24	commonly the result of progression of latent TB infection (LTBI) to TB disease. LTBI is a form
25	of TB in which a person is infected with Mycobacterium tuberculosis, the causative agent of TB,
26	but remains asymptomatic and noncontagious (2); if left untreated, LTBI can progress to TB
27	disease among $\leq 10\%$ of persons with LTBI within their lifetime (2). Because >85% of TB
28	disease cases among non-US-born persons residing in the United States are attributed to
29	progression of LTBI to TB disease (3,4), a substantial proportion of TB cases among non–US-
30	born persons is likely the result of progression of LTBI acquired before US arrival.
31	Consequently, the Centers for Disease Control and Prevention (CDC) recommend that efforts to
32	eliminate TB in the United States, in part, focus on LTBI detection and treatment among non-
33	US-born persons (5).

Understanding the factors associated with LTBI progression can help guide these efforts by identifying persons with LTBI who are at greatest risk of developing TB disease, allowing TB prevention resources to be concentrated on the populations at highest risk. Although persons recently infected with TB and persons with weakened immune systems are at higher risk for progressing to TB disease (6), the factors affecting the time required to develop TB disease remain unclear, particularly for non–US-born persons. Knowing such information can help

3

40	public health officials target interventions for LTBI testing and treatment for these persons
41	before LTBI progresses to TB disease. One study found the risk of developing TB disease among
42	non–US-born persons decreased with increasing time since US entry (7). However, non–US-
43	born persons are a heterogenous population who differ in health status based on country of origin
44	(8), and the effect of birth country on progression from LTBI to TB disease remains unclear. To
45	answer this question, we compared the time necessary for non-US-born persons to develop TB
46	disease after arrival in the United States according to birthplace.

47 <u>Methods</u>

Using US national TB surveillance data for 2011–2018, we assessed time to TB disease 48 diagnosis among non–US-born persons after US entry according to geographical birth region 49 50 (see "Research Design and Variables"); we categorized birth countries into regions because of the high number of countries represented among non–US-born persons with TB disease. We 51 assessed time to TB disease diagnosis as time from US entry to the time the TB case was 52 53 reported to a local or state health department, and we excluded persons with TB disease 54 attributed to recent transmission (3) to focus on persons whose TB disease was most likely caused by progression of LTBI acquired in their birth countries. We compared these times by 55 using bivariate and multivariate survival analysis, and we adjusted for age at TB disease 56 diagnosis, sex, and birth year. 57

58 Study Population

We derived the study population for this analysis from CDC's National Tuberculosis
Surveillance System (NTSS), which has been collecting information on TB disease cases in the
United States since 1953 (9). Case reports include demographic, clinical, and risk factor data.

4

NTSS's most recent TB surveillance case definition as of 2009 is available in the 2018 US TB surveillance report (1). For this study, we examined cases reported to NTSS from January 2011 through December 2018 among non–US-born persons (i.e., persons born outside the United States or its territories for whom neither parent was a US citizen) (birth countries and territories are listed in Appendix A). We excluded cases reported from the US territories or states freely associated with the United States (Figure 1).

We also excluded cases attributed to recent TB transmission in the United States by using 68 a previously published method that uses NTSS and genotypic data to determine likelihood of 69 recent transmission. This plausible-source case method attributes cases to recent transmission if 70 71 at least one plausible source case for the case of interest is identified in NTSS (3). With this method, cases are either attributed to recent transmission, not attributed to recent transmission, or 72 receive neither designation if they lack the necessary information to assess for recent 73 transmission (e.g., missing genotype data). By excluding cases attributed to recent transmission, 74 we were able to analyze cases that were more likely the result of LTBI progression. We further 75 excluded cases not attributed to recent transmission among persons for whom time from arrival 76 to TB disease diagnosis was ≤ 3 months because TB disease among such persons can represent 77 disease that was present at time of US entry rather than LTBI reactivation after US arrival; 78 79 excluding these cases also helps account for variability in TB disease screening overseas before US entry. 80

Finally, we excluded cases with missing data and observations with nonsensical values for a category (i.e., months to TB disease diagnosis <0, non–US-born persons with "United States" listed as birth country, or age less than number of months to TB disease diagnosis).

5

84 Research Design and Variables

We performed a bivariate analysis and a multivariate analysis examining the association 85 between birth country and time from initial US arrival to TB disease diagnosis, which was our 86 main outcome variable. In addition to birth country, we examined the following NTSS case 87 demographic variables as additional covariates for our analyses: age at TB disease diagnosis, 88 sex, and birth year. We performed the bivariate analysis to assess the association between time to 89 90 TB disease diagnosis and those variables individually, and we performed the multivariate analysis to account for the effects of the additional demographic variables on the association 91 between birth country and time to TB disease diagnosis. For our analyses, time to TB disease 92 diagnosis was the number of months spent in the United States before TB disease diagnosis, 93 which we derived by subtracting the date of initial US entry from the date that the TB disease 94 case was reported. We used the case report date because information regarding actual disease 95 diagnosis date was unavailable through NTSS; the report date represents the earliest notification 96 97 to a local public health agency that the patient might have TB disease. Because >200 non–US countries and territories of birth were reported to NTSS during the study timeframe, we used the 98 United Nations M49 standard, which categorizes countries and territories according to 99 geographic location and level of development, to divide these countries into 19 regions for ease 100 101 of statistical analysis (10,11) (see "Birth Country Categorization" in Appendix B). For our bivariate analysis, we categorized age into 6 categories, but we kept age as a continuous variable 102 for our multivariate analysis. We derived birth year by subtracting age from the year the case 103 104 was reported, and we categorized birth year into 6 categories; we included birth year in our analysis to adjust for a previously observed birth year cohort effect among non-US-born persons 105 with TB disease reported to NTSS (12). Finally, we excluded race/ethnicity as a covariate 106

6

because of multicollinearity with birth region (see "Exclusion of race/ethnicity variable" inAppendix B).

109 Statistical Analysis

We began by determining the number of patients who had TB disease not attributed to 110 recent transmission in each demographic category and determined the median number of months 111 (with interquartile range [IOR]) that these patients spent in the United States before receiving a 112 TB disease diagnosis. We also determined the median number of months according to birth 113 114 region and median age. We constructed a crude bivariate Kaplan-Meier survival curve to visually demonstrate the overall distribution of time to TB diagnosis since US entry. We then constructed 115 bivariate Kaplan-Meier curves stratified by each demographic covariate. We tested for 116 117 statistically significant differences between curves at $p \le 0.05$ by using the log rank test and reported global p values. 118

We then used Cox regression to examine the association of time to TB disease diagnosis and birth region, adjusting for the effects of age at diagnosis, sex, and birth year. We tested the proportional hazards assumption (see "Cox regression assumptions" in Appendix B), and because our data are likely double-truncated, we applied a correction for double-truncation to our sample set (*13*) (see "Double-truncation" in Appendix B). We reported adjusted hazard ratios (aHRs) with associated 95% confidence intervals (CIs) and p values from our Cox regression analysis.

Because the time after US entry at which persons who enter the United States with TB disease typically receive a diagnosis is unclear, previous studies have used a range of post-entry times to define cases as disease missed on entry as opposed to LTBI reactivation (*14–16*).

7

129	Therefore, we performed a sensitivity analysis to assess the effect of extending the exclusion
130	window from 3 months to 6 months for TB disease missed at time of entry for our Cox
131	regression analysis. Additionally, because TB in a child can be considered a sentinel event that
132	indicates recent transmission (17) , we performed a sensitivity analysis to assess the effect of
133	excluding children aged <5 years on the basis of previous research demonstrating that recent
134	transmission is most commonly observed among children in that age group $(3,4)$.
135	We performed all statistical analyses using R version 3.6.1, and we used the R code
136	developed by Rennert and Xie to correct for double truncation (13). All data were collected as
137	part of routine disease surveillance and were not part of human subjects research requiring

- 138 institutional review board approval.
- 139 <u>Results</u>

140 During 2011–2018, 79,159 TB cases were reported to NTSS (Figure 1). Of those cases, 28,745 cases were among US-born persons, were not reported from one of the 50 states or the 141 142 District of Columbia, or did not have a known origin of birth. We also excluded 15,655 cases that were either attributed to recent transmission or had no information regarding recent 143 transmission available; we excluded 2,906 cases for which the time to TB diagnosis was ≤ 3 144 months. Finally, we excluded 3,403 cases with missing information for ≥ 1 of the variables 145 considered; because only approximately 10% of the included cases had missing data for ≥ 1 146 variable, we performed listwise deletion of those cases for our analyses. As a result, we included 147 148 28,450 cases for our analyses.

The median number of months that a non–US-born person spent in the United States
before receiving a diagnosis of TB disease not attributed to recent transmission was 144 months

8

(IQR: 52–294 months). Persons from Middle Africa had the lowest median number of months 151 until TB diagnosis (26 months), and persons from Western Europe had the highest median 152 153 number of months (541 months) (Table 1). The median patient age was 48 years (IOR: 32–65 years). The highest proportion of non-US-born persons who developed TB disease not attributed 154 to recent transmission after arrival to the United States emigrated from Asia (Table 2); the 155 156 subregion or intermediary region with the highest proportion of non–US-born persons who received a TB diagnosis in the United States not attributed to recent transmission was South-157 158 eastern Asia.

Figures 2 and 3 display the Kaplan-Meier estimates for time to TB diagnosis, both crude 159 160 and stratified by birth region; Kaplan-Meier estimates for the other covariates are located in Appendix C (Figures C1-C3). For all 4 variables, we identified statistically significant 161 differences in the survival curves (p < 0.01 for each). Table 2 and Figure 4 display the results of 162 the Cox regression analysis: persons from Middle Africa had the highest hazard rate for 163 developing TB disease, compared with persons from Western Europe, after adjusting for age at 164 TB disease diagnosis, sex, and birth year (aHR = 7.02; 95% CI: 6.53–7.56); in other words, the 165 chance of TB disease diagnosis is 7 times higher for non–US-born persons from Middle Africa 166 than from Western Europe at any point during the study period, given that they did not 167 168 previously have TB disease. Persons from all other regions had significantly higher adjusted hazard rates than persons from Western Europe at $p \leq 0.05$, except for persons from Northern 169 America (i.e., Canada). The complete results of the Cox regression analysis, including aHRs for 170 age at TB disease diagnosis, sex, and birth year, are available in Table C1 (Appendix C). Finally, 171 after performing our sensitivity analyses, we observed that increasing the exclusion window 172

9

from ≤3 months to ≤6 months and excluding children aged <5 years changed the aHRs for all
persons by <10%, regardless of birth region (Table C2, Appendix C).

175 <u>Discussion</u>

176 On the basis of our analysis of NTSS data, the length of time for non–US-born persons to receive a TB diagnosis varied according to birth region. The highest aHRs for TB disease 177 178 diagnosis were concentrated among persons originating from Africa. In 2018, 5 of the 10 birth countries associated with the highest TB disease rates in the United States were African, and 179 180 Africa had the highest TB disease rate globally (1,18). It is unclear if an actual causal association 181 exists between higher overall TB disease rate in one's birthplace and one's likelihood of developing TB disease earlier. However, the World Health Organization's African Region had 182 183 the highest proportion of LTBI attributable to recent infection in 2014 (19), and persons are most likely to develop TB disease soon after TB infection (5). Therefore, shorter time to TB disease 184 diagnosis might be associated with higher annual risk of TB infection. Another possibility is that 185 US health care providers might have a higher suspicion for TB disease among certain 186 populations, particularly persons from countries with high TB rates, a known risk factor for 187 development of TB disease because of the higher risk for TB infection in those countries (5). 188 189 One other possibility is that these differences might reflect genetic differences between persons originating from different regions; certain host genetic factors have been associated with LTBI 190 191 progression to TB disease (20). Although these potential etiologies are compelling, the differences observed in this study may likely be the consequence of overall poorer health status 192 among persons from different regions, given lower levels of economic development and health 193 194 care access; 33 of the 47 least-developed countries in the world are located in Africa (21), and Africa has the lowest overall healthy life expectancy (i.e., the number of years that a newborn is 195

10

expected to live in good health) (22). Importantly, persons with poorer health status, particularly
malnutrition (23), might be more susceptible to developing TB disease, compared with healthier
persons.

The association between birth region and time to TB diagnosis may also be a 199 consequence of differences in risk factors for progression to TB disease among different regions. 200 Both HIV infection and diabetes mellitus are key risk factors for LTBI reactivation, with HIV 201 202 infection representing the greatest risk factor for LTBI reactivation (24); worldwide, 9% of incident TB cases in 2018 were among persons living with HIV, and 15% of TB cases might be 203 linked to diabetes mellitus (18,25). Additionally, the majority of high TB and HIV burden 204 countries are in Africa (16), and the HIV diagnosis rates for African-born persons living in the 205 United States are 6 times higher than the rate for the general US population (26). Given the 206 possibility of TB and HIV coinfection or TB and diabetes mellitus comorbidity as plausible 207 etiologies for the association between birth region and time to TB disease diagnosis, including 208 209 HIV status or diabetes mellitus diagnosis as variables in our analysis might appear reasonable. 210 However, even though NTSS offers information on HIV status and diabetes mellitus diagnosis, it does not offer information on the date of testing or diagnosis. Therefore, to use these data, we 211 would have to unjustifiably assume that a person's HIV status or presence of diabetes mellitus 212 213 were constant throughout the time from US entry to TB disease diagnosis date. This assumption 214 would also be invalid because global HIV incidence was likely low before the 1980s (27), and before 2010, HIV infection could prevent non-U.S. citizens from entering the United States (28). 215 216 In addition, including history of diabetes mellitus as a variable in this study would have resulted in an immortal time bias (29). For example, persons who received a diagnosis of diabetes 217 mellitus during the study period (i.e., before receiving a diagnosis of TB disease) must have 218

11

persisted long enough without a TB disease diagnosis to be diagnosed with diabetes mellitus; the 219 period of time from the start of the study period to diagnosis of diabetes mellitus for these 220 221 persons is known as *immortal time* because these persons might not have developed TB disease during that time interval. However, persons who have never received a diagnosis of diabetes 222 mellitus might have received their TB diagnosis during this immortal time, resulting in a 223 224 disadvantaged survival time despite not having a diabetes mellitus diagnosis. Therefore, we excluded HIV status and diabetes mellitus diagnosis as variables from this study. 225 Finally, all refugees entering the United States should undergo a domestic medical 226 examination upon US entry. Given that Africa and Asia together account for the highest 227 228 proportion of refugees coming to the United States since 2010 (30), their comparatively high aHRs in this study might be a consequence of TB disease diagnosis at the time of their domestic 229

230 medical evaluation, especially since TB screening is a recommended component of that

examination (31). However, the domestic medical examination is typically conducted 1-3

months after US entry (*32*), which is within our exclusion window for cases attributable to

233 imported TB disease. In addition, all refugees are screened for TB before US entry, making it

less likely that newly diagnosed TB would be detected following US entry.

235 Limitations

Our study had several limitations. First, the characteristics of persons who immigrate to the United States may not represent persons who remain in their birth country. One study reported that birth country TB incidence was 5.4 times higher than the US TB incidence for persons born in those countries who immigrated to the United States (*33*); another study found that the prevalence by birth country of isoniazid resistance and multidrug-resistant TB in the

12

United States better correlated with the prevalence by birth country seen in NTSS data than with 241 the prevalence seen in the birth countries themselves (34). This suggests that non–US-born 242 persons are not representative of the overall birth country population in terms of TB risk. 243 Additionally, NTSS does not report country of immediate origin, which can differ from birth 244 country, nor does NTSS account for interceding travel outside the United States after initial US 245 246 entry during which TB might have been transmitted. Finally, the health status of immigrants to the United States may be influenced by long-term US residence, causing it to diverge from 247 248 expected health status on the basis of birth country.

Additionally, our study does not account for the number of non–US-born persons emigrating from a particular region nor how those numbers change over time. It also does not account for reason for immigration, such as refugee status, which may affect risk for TB infection. Likewise, it does not account for age at arrival or arrival year because adjusting for these variables with age at diagnosis would indirectly adjust for the outcome variable and cause the aHRs to converge to unity; adjusting for either of these variables would potentially account for time exposed to TB in a birth region, which may affect overall TB infection risk.

Furthermore, by using regions to categorize countries in this study, we lose the ability to detect differences among those countries. Also, although the plausible-source-case method employed by NTSS has high accuracy compared with field-based assessments of recent transmission that use epidemiologic investigation methods, it is not completely accurate and might misclassify certain cases (*3*). Finally, we were unable to assess the effect of HIV status and diabetes mellitus on time to TB disease diagnosis.

262 Conclusion

13

263	Time to TB disease diagnosis among non-US-born persons varies by birth region, which
264	represents an important prognostic indicator for LTBI progressing to TB disease. Targeted LTBI
265	testing and treatment for persons entering the United States who were born in regions with high
266	aHRs might advance progress toward TB elimination in the United States. Additional studies
267	using data sources that include information on risk factors like HIV infection and diabetes
268	mellitus would be helpful in determining the potential influence of these comorbid conditions on
269	time to LTBI reactivation; such studies would also benefit from accounting for age at arrival and
270	TB rates in birth countries where feasible. Similar studies in countries with health care systems
271	comparable to the United States and diverse immigrant populations would also help determine if
272	these results are reproducible and could shed light on the etiology underlying regional
273	differences in time to TB disease diagnosis.
274	Acknowledgments
275	Andrew Hill; Carla A. Winston; Thomas R. Navin; Jonathan Wortham; Kristine M.
276	Schmit; Sandy P. Althomsons; Noah Schwartz; Rebekah Stewart; Peter Cegielski; Andrew
277	Vernon; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.
278	Author Bio
279	Amish Talwar is an Epidemic Intelligence Service Officer in the Division of Tuberculosis
280	Elimination at the Centers for Disease Control and Prevention in Atlanta. His primary research
281	interests include infectious disease prevention and global health.
202	Diselemne of Funding Counces

282 Disclosure of Funding Sources

14

- 283 Neither the authors nor their institutions at any time received payment or services from a third
- 284 party for any aspect of the submitted work.
- 285 **References**
- 1. Centers for Disease Control and Prevention (CDC)/Division of Tuberculosis Elimination.
- 287 Reported tuberculosis in the United States, 2018 [Internet]. Atlanta, GA: US Department
- of Health and Human Services, CDC; 2019 [cited 2020 February 21].
- 289 https://www.cdc.gov/tb/statistics/reports/2018/default.htm
- 290 2. Centers for Disease Control and Prevention (CDC)/Division of Tuberculosis Elimination.
- 291 Latent tuberculosis infection: a guide for primary health care providers [Internet].
- Atlanta, GA: US Department of Health and Human Services, CDC; 2013 [cited 2020
- February 21]. https://www.cdc.gov/tb/publications/ltbi/pdf/targetedltbi.pdf
- 3. France AM, Grant J, Kammerer JS, Navin TR. A field-validated approach using
- surveillance and genotyping data to estimate tuberculosis attributable to recent
- transmission in the United States. Am J Epidemiol. 2015;182:799–807.
- 297 doi:10.1093/aje/kwv121
- 4. Yuen CM, Kammerer JS, Marks K, Navin TR, France AM. Recent transmission of

tuberculosis—United States, 2011–2014. PLoS One. 2016;11:e0153728.

- doi:10.1371/journal.pone.0153728
- 5. Talwar A, Tsang CA, Price SF, Pratt RH, Walker WL, Schmit KM, et al. Tuberculosis—
- 302 United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68:257–62.

303	6.	Centers for Disease Control and Prevention (CDC)/Division of Tuberculosis Elimination.
304		TB risk factors [Internet]. Atlanta, GA: US Department of Health and Human Services,
305		CDC; 2016 [cited 2020 February 21]. https://www.cdc.gov/tb/topic/basics/risk.htm
306	7.	Menzies NA, Hill AN, Cohen T, and Salomon JA. The impact of migration on
307		tuberculosis in the United States. Int J Tuberc Lung Dis. 2018;22:1392–403.
308		doi:10.5588/ijtld.17.0185
309	8.	Argeseanu Cunningham S, Ruben JD, Narayan KM. Health of foreign-born people in the
310		United States: a review. Health Place. 2008;14:623–35.
311		doi:10.1016/j.healthplace.2007.12.002
312	9.	Yelk Woodruff RS, Pratt RH, Armstrong LR. The US National Tuberculosis Surveillance
313		System: a descriptive assessment of the completeness and consistency of data reported
314		from 2008 to 2012. JMIR Public Health Surveill. 2015;1:e15.
315		doi:10.2196/publichealth.4991
316	10	. United Nations Statistics Division. Standard country or area codes for statistical use
317		(M49) [Internet]. New York: United Nations; [cited 2020 March 2].
318		https://unstats.un.org/unsd/methodology/m49/
319	11.	. Committee for the Coordination of Statistical Activities. Note on definition of regions for
320		statistical analysis [Internet]. New York: United Nations Statistics Division; 2006 [cited
321		2020 February 26]. https://unstats.un.org/unsd/accsub/2006docs-8th/SA-2006-15-
322		Grouping-UNSD.pdf
323	12	. Iqbal SA, Winston CA, Bardenheier BH, Armstrong LR, Navin TR. Age-period-cohort
324		analyses of tuberculosis incidence rates by nativity, United States, 1996–2016. Am J
325		Public Health. 2018;108(Suppl4):S315-20. doi:10.2105/AJPH.2018.304687

326	13. Rennert L, Xie SX. Cox regression model with doubly truncated data. Biometrics.
327	2018;74:725–33. doi:10.1111/biom.12809
328	14. Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, et al; Tuberculosis
329	Epidemiologic Studies Consortium. Persistent latent tuberculosis reactivation risk in
330	United States immigrants. Am J Respir Crit Care Med. 2014;189:88–95. doi:
331	10.1164/rccm.201308-1480OC
332	15. Menzies HJ, Winston CA, Holtz TH, Cain KP, Mac Kenzie WR. Epidemiology of
333	tuberculosis among US- and foreign-born children and adolescents in the United States,
334	1994–2007. Am J Public Health. 2010;100:1724–9. doi:10.2105/AJPH.2009.181289
335	16. Cain KP, Benoit SR, Winston CA, Mac Kenzie WR. Tuberculosis among foreign-born
336	persons in the United States. JAMA. 2008;300:405-12. doi:10.1001/jama.300.4.405
337	17. Holmberg PJ, Temesgen Z, Banerjee R. Tuberculosis in children. Pediatr Rev.
338	2019;40:168–78. Erratum in: Pediatr Rev. 2019;40:318. doi:10.1542/pir.2018-0093
339	18. World Health Organization. Global tuberculosis report 2019 [Internet]. Geneva: World
340	Health Organization; 2019 [cited 2020 February 26].
341	https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
342	19. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation
343	using mathematical modelling. PLoS Med. 2016;13(10):e1002152.
344	doi:10.1371/journal.pmed.1002152
345	20. Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, et al. Genetics of
346	human susceptibility to active and latent tuberculosis: present knowledge and future
347	perspectives. Lancet Infect Dis. 2018;18:e64-75. doi:10.1016/S1473-3099(17)30623-0

348	21.	United Nations Conference on Trade and Development. Least developed countries
349		(LDCs) [Internet]. Geneva: United Nations Conference on Trade and Development;
350		[cited 2020 February 26].
351		https://unctad.org/en/Pages/ALDC/Least%20Developed%20Countries/LDCs.aspx
352	22.	World Health Organization. World health statistics 2019: monitoring health for the SDGs
353		[Internet]. Geneva: World Health Organization; 2019 [cited 2020 February 26].
354		https://apps.who.int/iris/bitstream/handle/10665/324835/9789241565707-eng.pdf?ua=1
355	23.	Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis:
356		evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis.
357		2004;8(3):286–298.
358	24.	Centers for Disease Control and Prevention (CDC)/Division of Tuberculosis Elimination.
359		Transmission and Pathogenesis of Tuberculosis [Chapter 2]. In: Core curriculum on
360		tuberculosis: what the clinician should know. 6th ed. Atlanta: US Department of Health
361		and Human Services, CDC; 2013: 19-44.
362	25.	World Health Organization. Tuberculosis & diabetes [Internet]. Geneva: World Health
363		Organization; 2019 [cited 2020 February 26].
364		https://www.who.int/tb/publications/diabetes_tb.pdf
365	26.	Blanas DA, Nichols K, Bekele M, Lugg A, Kerani RP, Horowitz CR. HIV/AIDS among
366		African-born residents in the United States. J Immigr Minor Health. 2013;15:718–24.
367		doi:10.1007/s10903-012-9691-6
368	27.	GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence,
369		prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.
370		Lancet HIV. 2016;3(8):e361-e387. doi:10.1016/S2352-3018(16)30087-X

371	28. Centers for Disease Control and Prevention (CDC). Final rule removing HIV infection
372	from U.S. immigration screening [Internet]. Atlanta, GA: US Department of Health and
373	Human Services, CDC; 2011 [cited 2020 April 20].
374	https://www.cdc.gov/immigrantrefugeehealth/laws-regs/hiv-ban-removal/final-rule-
375	technical-qa.html
376	29. Shariff SZ, Cuerden MS, Jain AK, Garg AX. The secret of immortal time bias in
377	epidemiologic studies. J Am Soc Nephrol. 2008;19:841–3.
378	doi:10.1681/ASN.2007121354
379	30. Department of Homeland Security (US). Refugee arrivals by region and country of
380	nationality: fiscal years 2009 to 2018 [Internet]. Washington: US Department of
381	Homeland Security; [updated 2020 January 9, cited 2020 February 26].
382	https://www.dhs.gov/sites/default/files/publications/immigration-
383	statistics/yearbook/2018/yrbk_2018_rfa_excel_final.zip
384	31. Centers for Disease Control and Prevention (CDC)/Division of Tuberculosis Elimination.
385	Guidelines for screening for tuberculosis infection and disease during the domestic
386	medical examination for newly arrived refugees [Internet]. Atlanta: US Department of
387	Health and Human Services, CDC; 2019 [cited 2020 February 26].
388	https://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/tuberculosis-
389	guidelines.html
390	32. Mitchell T, Weinberg M, Posey DL, Cetron M. Immigrant and refugee health: a Centers
391	for Disease Control and Prevention perspective on protecting the health and health
392	security of individuals and communities during planned migrations. Pediatr Clin North
393	Am. 2019;66:549–60. doi:10.1016/j.pcl.2019.02.004

394	33. Tsang CA, Langer AJ, Kammerer JS, Navin TR. US Tuberculosis Rates among Persons
395	Born Outside the United States Compared with Rates in Their Countries of Birth, 2012-
396	2016 ¹ . Emerg Infect Dis. 2020;26(3):533-540. doi:10.3201/eid2603.190974
397	34. Taylor AB, Kurbatova EV, Cegielski JP. Prevalence of anti-tuberculosis drug resistance
398	in foreign-born tuberculosis cases in the U.S. and in their countries of origin. PLoS One.
399	2012;7(11):e49355. doi:10.1371/journal.pone.0049355
400	
401	Address for correspondence: Amish Talwar, Centers for Disease Control and Prevention,
402	1600 Clifton Rd NE, Mailstop US12-4, Atlanta, GA, 30329, USA; phone number: +1-404-
403	718-7207; e-mail: atalwar@cdc.gov
404	

20

- 405 **Table 1.** Median time to diagnosis of tuberculosis disease not attributed to recent transmission
- 406 for non–US-born persons by region United States, 2011–2018

407

	Median time to
	tuberculosis disease
Region	diagnosis (months)
Africa	53
Eastern Africa	62
Middle Africa	26
Northern Africa	64
Southern Africa	77
Western Africa	46
Americas	162
Caribbean	127
Central America	175
Northern America*	353
South America	142
Asia	157
Central Asia	60
Eastern Asia	211
South-eastern Asia	190
Southern Asia	76
Western Asia	83
Europe	214
Eastern Europe	178
Northern Europe	455
Southern Europe	223
Western Europe	541
Oceania	67

408 * Excludes the United States of America.

21

410 **Table 2.** Adjusted hazard ratio (aHR) estimates of tuberculosis disease diagnosis for non–U.S-

born persons with tuberculosis disease not attributed to recent transmission, adjusting for age at

diagnosis, sex, and birth year (n = 28,450) — United States, 2011–2018

413

Region	No. (%)	aHR	95% CI	p value
Africa	2,910 (10.2)			
Eastern Africa	1,627 (5.7)	3.91	(3.67–4.17)	<0.01
Middle Africa	286 (1.0)	7.02	(6.53–7.56)	<0.01
Northern Africa	126 (0.4)	3.43	(3.15-3.75)	<0.01
Southern Africa	56 (0.2)	4.19	(3.74–4.70)	<0.01
Western Africa	815 (2.9)	4.84	(4.54-5.17)	<0.01
Americas	9,719 (34.2)			
Caribbean	1,241 (4.4)	2.82	(2.65–3.01)	<0.01
Central America	7,114 (25.0)	2.03	(1.91-2.15)	<0.01
Northern America*	20 (0.1)	1.13	(0.99-1.29)	0.07
South America	1,344 (4.7)	2.85	(2.68-3.03)	<0.01
Asia	14,999 (52.7)			
Central Asia	45 (0.2)	4.71	(4.17–5.32)	<0.01
Eastern Asia	2,924 (10.3)	2.88	(2.71–3.07)	<0.01
South-eastern Asia	7,812 (27.5)	3.06	(2.89–3.26)	<0.01
Southern Asia	4,026 (14.2)	4.29	(4.04–4.57)	<0.01
Western Asia	192 (0.7)	3.34	(3.09–3.62)	<0.01
Europe	669 (2.4)			
Eastern Europe	328 (1.2)	2.77	(2.58–2.98)	<0.01
Northern Europe	47 (0.2)	1.12	(1.01–1.23)	0.03
Southern Europe	226 (0.8)	1.25	(1.17–1.35)	<0.01
Western Europe†	68 (0.2)	NA	NA	NA
Oceania	153 (0.5)	2.78	(2.56–3.02)	<0.01
Australia and New Zealand	1 (0.004)	NA	NA	NA
Melanesia	10 (0.04)	NA	NA	NA
Micronesia	113 (0.4)	NA	NA	NA
Polynesia	29 (0.1)	NA	NA	NA

414 Abbreviations: CI: confidence interval; NA: not available.

415 * Excludes the United States of America.

416 † Indicates reference value.

22



419 **Figure 1.** Flow chart of analysis cohort selection process.

420



Figure 2. Kaplan-Meier estimates for time to tuberculosis (TB) disease diagnosis n
to recent transmission for non–US-born persons — United States, 2011–2018.

424



425

Figure 3. Kaplan-Meier estimates for time to tuberculosis (TB) disease diagnosis not attributed
to recent transmission for non–U.S.-born persons stratified by region of birth (see Appendix A
for list of countries) — United States, 2011–2018.

25

434 Appendix A for list of countries) — United States, 2011–2018.